Review
Nature Reviews Drug Discovery 6, 464-479 (June 2007) | doi:10.1038/nrd2111
Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases
Michael P. Mazanetz1 & Peter M. Fischer1 About the authors
Abstract
Aggregation of hyperphosphorylated tau is one of the characteristic neuropathological lesions of Alzheimer's disease and other neurodegenerative disorders. Pharmacological modulation of tau hyperphosphorylation might represent a valid and feasible therapeutic strategy for such disorders. Here, we consider recent evidence supporting the validity of the three most relevant kinases affecting tau hyperphosphorylation — GSK3
, CDK5 and ERK2 — as drug targets and describe progress in the design of inhibitors for these kinases.
- View At a Glance
Author affiliations
- Centre for Biomolecular Sciences and School of Pharmacy, University of Nottingham, University Park, Nottingham NG7 2RD, UK.
Correspondence to: Peter M. Fischer1 Email: peter.fischer@nottingham.ac.uk
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Teasing out the tanglesNature Medicine News and Views (01 Jul 2006)
Untangling memory deficitsNature Medicine News and Views (01 Aug 2005)
See all 6 matches for News And ViewsRESEARCH
Hyperphosphorylated tau in parahippocampal cortex impairs place learning in aged mice expressing wild-type human tauThe EMBO Journal Article (12 Dec 2007)
See all 4 matches for Research
